Gordon's syndrome (GS) is a salt-sensitive, hyperkalaemic, familial hypertension syndrome which may masquerade in milder forms as essential hypertension. The response of hyperakalaemia to dietary salt restriction and to mineralocorticoids is heterogeneous, suggesting genetic heterogeneity. In a recently published study using small pedigrees, possible linkage of GS to chromosomes 1 and 17 was described. Studying the largest pedigree so far reported with GS, and using fluorescentlabelled microsatellite markers, we sought evidence of linkage to chromosomes 1 and 17. In this family there was no segregation of GS with any of the markers for
Introduction
When no secondary cause for hypertension is obvious, or can be identified after investigation (which varies in intensity), the hypertension is called primary or essential. 'Essential hypertension' is of course a heterogeneous non-entity, probably caused by a very large number of different interactions between genetic and environmental influences. An intriguing question is whether some of the already described genetic causes of hypertension may, in less readily recognisable forms, contribute significantly to the large proportion of hypertensives currently labelled 'essential'.
Some of the currently recognised 'secondary' forms of hypertension, such as Cushing's syndrome, phaeochromocytoma, renal artery stenosis (when due to fibromuscular disease) and non-glucocorticoid-suppressible primary aldosteronism can occur in familial forms, where genetic influences are clearly highly penetrant within certain families. With the exception of phaeochromocytoma (when part of MEN-II) the responsible genetic mutations have not been described, and with the exception of primary aldosteronism, these are probably rare causes of hypertension. There are, however, several 'monogenic' forms of hypertension 1 (Table 1) where the genetic defect has been identified, and its expression leads to inappropriate renal sodium reabsorption and a salt-sensitive form of hypertension. While these forms have been labelled 'monogenic', minor degrees of genetic heterogeneity have already been described in some of them. 2 A familial, salt-sensitive form of hypertension which is clinically distinguishable because of its association with hyperkalaemia (despite normal glomerular filtration rate) has until recently eluded any resolution in genetic terms. Gordon's syndrome (or pseudohypoaldosteronism type II) is characterised clinically by a dominant pattern of inheritance, and can cause severe hypertension. 3, 4 Hyperkalaemia is present from birth in affected subjects, but, as in glucocorticoid-remediable hyperaldosteronism, hypertension may not develop until much later in life, and is of varying severity. Since hyperkalaemia is also of varying severity, however, like glucocorticoid-remediable hyperaldosteronism, Gordon's syndrome (GS) may exist in forms which are indistinguishable from essential hypertension. The detection of (GS) is made more difficult by the reluctance of clinicians to accept a raised serum or plasma potassium as a definite abnormality, often attributing it to the not uncommon partial haemolysis which results from difficult venepunctures, or even the use of vacuum tubes. Collection of a venous blood sample from the arm with a tourniquet in place, especially if repeated muscle contraction is used to distend veins, can elevate potassium levels by 1 mmol/l. 5 Thus, clinicians are accustomed to seeing mild hyperkalaemia and ignoring it. While some of the reported patients with GS have had potassium levels 7 to 8.5 mmol/l, others have been more mildly hyperkalaemic. It would be surprising if some patients with the genetic mutation of GS did not have plasma potassium levels below the accepted upper limit of normal.
Hyperchloremic acidosis, reduced bicarbonate levels and normal glomerular filtration rate are the other biochemical features of GS. 3, 4 In its severest form, the syndrome is associated with short stature, muscle weakness and intellectual impairment, thought due to the severe hyperkalaemic acidosis. 3, 4 Clearly, a genetic test using peripheral blood DNA would be necessary to identify all affected subjects, and define the syndrome in its milder forms. The first step towards such a peripheral blood test would be identification of the gene or genes responsible.
Recently, Lifton and associates 6 utilized DNA from a number of small families with GS to undertake a genome-wide screen, looking for evidence of genetic linkage amongst a panel of over 250 microsatellite markers covering all 22 autosomes. Each family contained too few informative individuals to establish linkage using conventional methods. Linkage to broad areas of chromosomes 1 (1q31-42; 68% of families) and 17 (17p11-q21; 32% of families) were found. Although the linkage to chromosome 17 was poorly localised, it did include an area of particular interest in the study of the genetics of hypertension. This segment of chromosome 17 overlaps with an area homologous with a region of rat chromosome 10 which has been linked to hypertension in some inbred strains of spontaneously hypertensive rats (SHR). [7] [8] [9] Of greater interest to those treating human hypertension, this area of chromosome 17 has also been recently linked to human familial essential hypertension, 10 and it is possible that the same genetic locus for hypertension is involved in both 'essential hypertension' and GS. 11 While most of the reported patients with GS respond to dietary salt restriction or administered mineralocorticoid with a reduction in plasma potassium, a significant sub-population do not, allowing us to predict genetic heterogeneity for this condition. 2, 4 This is supported by the report of Mansfield et al 6 of linkage to two different loci (chromosomes 1 and 17).
The present paper reports our investigations in a relatively large and well characterised Brisbanebased family with seven offspring clearly affected by GS. Linkage to chromosome 1 could be excluded. Affected, but no unaffected, members share the same alleles for markers in the same area of chromosome 17 to which linkage was shown in the above SHR and essential hypertension studies.
Materials and methods
The Brisbane pedigree is shown in Figure 1 . The phenotypic details have been previously described in full elsewhere. 12 The trait appears to segregate as an autosomal dominant in this pedigree and the presence of seven affected offspring over two generations suggested that it is also highly penetrant.
Genomic DNA was obtained from a peripheral venous blood sample. Various microsatellite markers (all CA repeats) were then amplified using the polymerase chain reaction using fluorescent labelled primers according to published methods with minor modifications. 13 The fluorescent products were combined and run either on an AB1 373 or 377 semiautomated sequencer. The sizes of the markers, reflecting differences in the number of CA repeats, were assigned using version 2 of the AB1 Genotyper ® software. Linkage analysis was performed with the LINKAGE software package (version 5.2) for 2-point analysis and the GENEHUNTER program for multipoint (Microsoft Windows version 1.2 available from http://www.fallingrain.com). The programs were implemented and run on a Pentium ® II microprocessor.
Results
There was no evidence that the Gordon's phenotype in this family segregates with any of the microsatellite markers previously reported to establish linkage of certain small GS families to chromosome 1. In the Brisbane pedigree, linkage to this area of chromosome 1 could be excluded with LOD scores of р2 for all of the markers. This LOD score (logarithm 10 of the likelihood ratio of linkage vs non-linkage) corresponds to a threshold odds of at least 1:100 against linkage.
In contrast, evidence for linkage was found using a set of markers covering a span of some 63 centimorgans (cM) on chromosome 17 ( Table 2 ). The maximum LOD scores were obtained with markers D17S250 and D17S934. Significantly, the LOD scores of around 2.3 for both markers (assuming that the GS trait is fully penetrant) were very close to the maximum expected LOD score for this pedigree. This indicates that almost all of the genetic information has been extracted by this analysis and strongly suggests linkage of the GS trait to this region of the long arm of chromosome 17. Inspection of the individual haplotypes confirmed that there was no recombination between the GS trait and individual markers for the region of 17q bounded by D17S798 and D17S787. Multipoint linkage analysis using all of the markers cited in Table 1 confirmed the 2-point result, with a maximum multipoint LOD score of 2.40 over the region bounded by markers D17S250 and D17S934 (Figure 2) .
Discussion
In the last 5 years, considerable advances have been made in our understanding of the molecular genetics of certain familial forms of hypertension such as Liddle's syndrome and the syndrome of apparent mineralocorticoid excess. 1 Until recently, however, there were no clues to the molecular basis of GS, another variety of salt-sensitive familial hypertension. Important progress was made in the recent study by Mansfield et al, 6 in which evidence for linkage to chromosomes 1 and 17 was found. However, only three of the eight pedigrees examined individually provided a LOD score Ͼ1 to either of the putative loci identified. None of the published pedigrees contained sufficient numbers of affected members to provide LOD scores above the threshold value of 3 usually preferred to confirm linkage. The areas of interest on chromosomes 1 and 17 were rather poorly defined, spanning 33 and 43cM respectively, but provide a basis for further study.
The next step is to evaluate putative loci in larger, well characterised GS pedigrees such as the Brisbane pedigree examined in this study. Using the same marker panel as reported by the Mansfield group, we can exclude linkage to chromosome 1 and confirm linkage to the long arm of chromosome 17 in this pedigree.
Although essential hypertension has a substantial genetic component, it is almost certainly polygenic, reflecting the operation of many rather than the single genes responsible for the rarely recognised familial hypertension syndromes. Hence it is of great relevance that Julier et al, 10 using affected pairs of Caucasian essential hypertensives, have identified a quantitative trait locus on the long arm of chromosome 17 in human familial essential hypertension. 10 From the panel of markers used (which did not include D17S250), the strongest evidence for linkage occurred with D17S934 and the region telemeric to this marker. It is also intriguing that this region of human chromosome 17 shows conservation of synteny with a region of rat chromosome 10 which has itself been shown to contain a hypertensive QTL in crosses involving several different hypertensive rat strains. [7] [8] [9] The ACE gene is located within both of these regions, and recently has been linked again to essential hypertension, 11 but has been excluded as a candidate gene for either of the above QTLS. 9, 10 Mutation scanning of the only other candidate gene so far mapped to this interval of 17q, the chloridebicarbonate anion exchanger (AE1), excluded it in the only previously published genetic study of GS of which we are aware. 6 Our linkage results with the Brisbane pedigree suggest that the locus for GS lies within a 34cM region bounded by D17S793 and D17S809, and centred on D17S934, a region containing a human hypertensive QTL, itself syntenic with a QTL in the rat. Since the gene for GS may be the same gene responsible for the hypertensive QTL on 17q, its identification is of the highest priority. Furthermore, if the hypertension susceptibility gene on 17q is the gene for GS, then the GS phenotype may be greatly under diagnosed amongst the larger population of essential hypertensives. Only with a clearer understanding of the molecular basis of GS is this likely to become apparent.
